INTS
What one share of Intensity Therapeutics holds
Biological Products, (No Diagnostic Substances)
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction leading to anti-cancer immune activation. Our new approach involves the direct injection into tumors of a unique product created from our DfuseRxSM discovery platform.
Intensity Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$4.80 |
|---|---|
| Cash and investments | $3.23 |
| Book value | $3.13 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | — | −$55.58 | — | −$40.15 | — | −$110.69 |
| 2023 | — | −$34.42 | — | −$20.91 | — | $24.00 |
| 2024 | — | −$29.24 | — | −$27.36 | — | $4.82 |
| 2025 | — | −$8.56 | — | −$6.81 | — | $4.70 |